



NOVALAB CORP
 Address: 87 Berdan Ave Suite 2A,
 Wayne, NJ 07470
 CLIA# : 31D2140750 | Lab Director: Sinisa Ivelja
 Ph# 973-832-7902 | FAX# 973-832-7980
 Email: info@novalabcorp.com

PLEASE SUBMIT THE FOLLOWING WITH REQUISITION FORM

- Statement of Medical Necessity (Signed by Physician)
- Informed Consent Form (Signed by Pt & Physician)
- SOAP & Progress Note (Signed by Physician)

CANCERGENOMICS TESTING REQUISITION FORM

PATIENT INFORMATION

Patient First Name		Patient Last Name		Biological Sex <input type="checkbox"/> F <input type="checkbox"/> M
Date of Birth (MM/DD/YYYY)		Phone Number	Email	
Address	City	State	Zip	
Ethnicity: <input type="checkbox"/> African American <input type="checkbox"/> Asian <input type="checkbox"/> Caucasian <input type="checkbox"/> Hispanic <input type="checkbox"/> Jewish(Ashkenazi) <input type="checkbox"/> Portuguese <input type="checkbox"/> Other				

PATIENT INSURANCE INFORMATION

SPECIMEN INFORMATION

<input type="checkbox"/> Insurance <input type="checkbox"/> Self-Pay <input type="checkbox"/> Client Bill		Date Sample Collected (mm/dd/yyyy)	
Name of the insurance	Secondary Insurance, If any		
Insurance Policy/ID number	Name of the insured		
Insurance Group number	Date of Birth of Insured		
		<input type="checkbox"/> Buccal Swab <input type="checkbox"/> Other (specify source)	

ORDERING PHYSICIAN/SENDING FACILITY (Each Listed person will receive a copy of the report)

Facility Name (Facility Code):	Address:	City:	
State/Country :	Zip:	Phone:	
Ordering Licensed Provider Name (Last, First)(Code)	NPI#	Phone	Fax/Email

STATEMENT OF MEDICAL NECESSITY

By submission of this test requisition and accompanying sample(s), I: (i) authorize and direct to perform the testing indicated; (ii) certify that the person listed as the ordering provider is authorized by law to order the test(s) requested; (iii) certify that any custom panel and/or ordered test(s) requested on this test requisition form are reasonable and medically necessary for the diagnosis and/or treatment of a disease, illness, impairment, symptom, syndrome or disorder; (iv) the test results will determine my patient's medical management and treatment decisions of this patient's condition on this date of service; (v) have obtained this patient's and relatives', when applicable, written informed consent to undergo any genetic testing requested; and (vi) that the full and appropriate diagnosis code(s) are indicated to the highest level of specificity.

Signature of Provider (required)

Date:

INDICATIONS FOR TESTING (CHECK ALL THAT APPLY)

Diagnostic Family history Positive or normal control Other.....

Will Patient management be changed depending on the test results? Yes No

CLINICAL HISTORY

Attach any available detailed medical records and clinical notes

Clinical Presentation

Please indicate any clinical presentations and/or Endings that may be relevant to genetic testing:

There are many presentations which may not seem like a direct association for disease. Please list the most suspected presentations and attach detailed medical records and/or pedigree.

PATIENT CLINICAL HISTORY

Cancer /Tumer	Age at DX	Pathology and Other info				
Breast		Type:	ER <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	PR <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	HER2/neu <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	
2nd primary breast		Type:	ER <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	PR <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	HER2/neu <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	
Ovarian		Fallopian tube	Primary peritoneal			
Prostate		Gleason score:				
Hematologic		Type:	Allogeneic bone marrow or peripheral stem cell transport			
Other Cancer		Type:				

Other clinical history:

Pre- Genetic Counselling:
Please Refer case to a genetic counselling institution if Genetic counseling is required by patients benefits.

Targeted Single Gene Testing Panel (Select the genes below) or Comprehensive CGx Testing Panel (Test All Genes)

- | | | | | | | | |
|---------------------------------|--------------------------------|---------------------------------|---------------------------------|--------------------------------|--------------------------------|-------------------------------|---------------------------------|
| <input type="checkbox"/> MUTYH | <input type="checkbox"/> CDK4 | <input type="checkbox"/> FBN1 | <input type="checkbox"/> COL1A1 | <input type="checkbox"/> BRCA1 | <input type="checkbox"/> MSH2 | <input type="checkbox"/> MITF | <input type="checkbox"/> PMS2 |
| <input type="checkbox"/> PTEN | <input type="checkbox"/> GJB2 | <input type="checkbox"/> GREM1 | <input type="checkbox"/> BRIP1 | <input type="checkbox"/> SMAD4 | <input type="checkbox"/> BARD1 | <input type="checkbox"/> BAP1 | <input type="checkbox"/> NBN |
| <input type="checkbox"/> BMPR1A | <input type="checkbox"/> GJB6 | <input type="checkbox"/> PALB2 | <input type="checkbox"/> TP53 | <input type="checkbox"/> STK11 | <input type="checkbox"/> MSH6 | <input type="checkbox"/> KIT | <input type="checkbox"/> CDKN2A |
| <input type="checkbox"/> ATM | <input type="checkbox"/> BRCA2 | <input type="checkbox"/> CDH1 | <input type="checkbox"/> NF1 | <input type="checkbox"/> POLD1 | <input type="checkbox"/> CHEK2 | <input type="checkbox"/> TERT | |
| <input type="checkbox"/> POLE | <input type="checkbox"/> BLM | <input type="checkbox"/> RAD51D | <input type="checkbox"/> RAD51C | <input type="checkbox"/> EPCAM | <input type="checkbox"/> MLH1 | <input type="checkbox"/> APC | |

INDICATION (S) FOR TESTING **ICD-10 Codes**

- | | |
|---|--|
| <ul style="list-style-type: none"> <input type="checkbox"/> C25.0 - Malignant neoplasm of head of pancreas <input type="checkbox"/> C25.1 - Malignant neoplasm of body of pancreas <input type="checkbox"/> C25.2 - Malignant neoplasm of tail of pancreas <input type="checkbox"/> C25.3 - Malignant neoplasm of pancreatic duct <input type="checkbox"/> C25.4 - Malignant neoplasm of endocrine pancreas <input type="checkbox"/> C25.7 - Malignant neoplasm of other parts of pancreas <input type="checkbox"/> C25.8 - Malignant neoplasm of overlapping sites of pancreas <input type="checkbox"/> C25.9 - Malignant neoplasm of pancreas, unspecified <input type="checkbox"/> C50.011 - Malignant neoplasm of nipple and areola, right female breast <input type="checkbox"/> C50.012 - Malignant neoplasm of nipple and areola, left female breast <input type="checkbox"/> C50.021 - Malignant neoplasm of nipple and areola, right male breast <input type="checkbox"/> C50.022 - Malignant neoplasm of nipple and areola, left male breast <input type="checkbox"/> C50.111 - Malignant neoplasm of central portion of right female breast <input type="checkbox"/> C50.112 - Malignant neoplasm of central portion of left female breast <input type="checkbox"/> C50.121 - Malignant neoplasm of central portion of right male breast <input type="checkbox"/> C50.122 - Malignant neoplasm of central portion of left male breast <input type="checkbox"/> C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast <input type="checkbox"/> C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast <input type="checkbox"/> C50.221 - Malignant neoplasm of upper-inner quadrant of right male breast <input type="checkbox"/> C50.222 - Malignant neoplasm of upper-inner quadrant of left male breast <input type="checkbox"/> C50.311 - Malignant neoplasm of lower-inner quadrant of right female breast <input type="checkbox"/> C50.312 - Malignant neoplasm of lower-inner quadrant of left female breast <input type="checkbox"/> C50.321 - Malignant neoplasm of lower-inner quadrant of right male breast <input type="checkbox"/> C50.322 - Malignant neoplasm of lower-inner quadrant of left male breast <input type="checkbox"/> C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast <input type="checkbox"/> C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast <input type="checkbox"/> C50.421 - Malignant neoplasm of upper-outer quadrant of right male breast <input type="checkbox"/> C50.422 - Malignant neoplasm of upper-outer quadrant of left male breast <input type="checkbox"/> C50.511 - Malignant neoplasm of lower-outer quadrant of right female breast <input type="checkbox"/> C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast <input type="checkbox"/> C50.521 - Malignant neoplasm of lower-outer quadrant of right male breast | <ul style="list-style-type: none"> <input type="checkbox"/> C50.522 - Malignant neoplasm of lower-outer quadrant of left male breast <input type="checkbox"/> C50.611 - Malignant neoplasm of axillary tail of right female breast <input type="checkbox"/> C50.612 - Malignant neoplasm of axillary tail of left female breast <input type="checkbox"/> C50.621 - Malignant neoplasm of axillary tail of right male breast <input type="checkbox"/> C50.622 - Malignant neoplasm of axillary tail of left male breast <input type="checkbox"/> C50.811 - Malignant neoplasm of overlapping sites of right female breast <input type="checkbox"/> C50.812 - Malignant neoplasm of overlapping sites of left female breast <input type="checkbox"/> C50.821 - Malignant neoplasm of overlapping sites of right male breast <input type="checkbox"/> C50.822 - Malignant neoplasm of overlapping sites of left male breast <input type="checkbox"/> C50.911 - Malignant neoplasm of unspecified site of right female breast <input type="checkbox"/> C50.912 - Malignant neoplasm of unspecified site of left female breast <input type="checkbox"/> C50.921 - Malignant neoplasm of unspecified site of right male breast <input type="checkbox"/> C50.922 - Malignant neoplasm of unspecified site of left male breast <input type="checkbox"/> C56.1 - Malignant neoplasm of right ovary <input type="checkbox"/> C56.2 - Malignant neoplasm of left ovary <input type="checkbox"/> C56.3 - Malignant neoplasm of bilateral ovaries <input type="checkbox"/> C57.01 - Malignant neoplasm of right fallopian tube <input type="checkbox"/> C57.02 - Malignant neoplasm of left fallopian tube <input type="checkbox"/> C61 - Malignant neoplasm of prostate <input type="checkbox"/> D05.01 - Lobular carcinoma in situ of right breast <input type="checkbox"/> D05.02 - Lobular carcinoma in situ of left breast <input type="checkbox"/> D05.11 - Intraductal carcinoma in situ of right breast <input type="checkbox"/> D05.12 - Intraductal carcinoma in situ of left breast <input type="checkbox"/> D05.81 - Other specified type of carcinoma in situ of right breast <input type="checkbox"/> D05.82 - Other specified type of carcinoma in situ of left breast <input type="checkbox"/> D05.91 - Unspecified type of carcinoma in situ of right breast <input type="checkbox"/> D05.92 - Unspecified type of carcinoma in situ of left breast <input type="checkbox"/> Z85.07 - Personal history of malignant neoplasm of pancreas <input type="checkbox"/> Z85.3 - Personal history of malignant neoplasm of breast <input type="checkbox"/> Z85.43 - Personal history of malignant neoplasm of ovary <input type="checkbox"/> Z85.46 - Personal history of malignant neoplasm of prostate |
|---|--|

SECONDARY TYPES OF CANCER SYMPTOMS

- | | | |
|---|--|--|
| <ul style="list-style-type: none"> <input type="checkbox"/> C16.0 - Malignant neoplasm of cardia <input type="checkbox"/> C16.4 - Malignant neoplasm of pylorus <input type="checkbox"/> C17.0 - Malignant neoplasm of duodenum <input type="checkbox"/> C17.1 - Malignant neoplasm of jejunum <input type="checkbox"/> C17.2 - Malignant neoplasm of ileum <input type="checkbox"/> C18.0 - Malignant neoplasm of cecum <input type="checkbox"/> C20 - Malignant neoplasm of rectum <input type="checkbox"/> C21.1 - Malignant neoplasm of anal canal <input type="checkbox"/> C22.0 - Liver cell carcinoma <input type="checkbox"/> C22.1 - Intrahepatic bile duct carcinoma <input type="checkbox"/> C22.2 - Hepatoblastoma <input type="checkbox"/> C55 - Malignant neoplasm of uterus part unspci ed <input type="checkbox"/> C62.12 - Malignant neoplasm of descended testis <input type="checkbox"/> 17.9 - Malignant neoplasm of small intestine unspecified <input type="checkbox"/> C22.9 - Malignant neoplasm of liver, not specified as primary <input type="checkbox"/> C24.9 - Malignant neoplasm of biliary tract unspecified <input type="checkbox"/> C26.0 - Malignant neoplasm of intestinal tract part unspecified <input type="checkbox"/> C18.1 - Malignant neoplasm of appendix <input type="checkbox"/> C63.9 - Malignant neoplasm of male genital organ, unspecified <input type="checkbox"/> C15.3 - Malignant neoplasm of upper third of esophagus <input type="checkbox"/> C15.8 - Malignant neoplasm of overlapping sites of esophagus <input type="checkbox"/> C17.3 - Meckel's diverticulum malignant <input type="checkbox"/> C16.8 - Malignant neoplasm of overlapping sites of stomach <input type="checkbox"/> C17.8 - Malignant neoplasm of overlapping sites of small intestine <input type="checkbox"/> C18.8 - Malignant neoplasm of overlapping sites of colon <input type="checkbox"/> C21.8 - Malignant neoplasm of overlapping sites of rectum, anus <input type="checkbox"/> C24.8 - Malignant neoplasm of overlapping sites of biliary tract | <ul style="list-style-type: none"> <input type="checkbox"/> C22.3 - Angiosarcoma of liver <input type="checkbox"/> C22.4 - Other sarcomas of liver <input type="checkbox"/> C23 - Malignant neoplasm of gallbladder <input type="checkbox"/> C26.1 - Malignant neoplasm of spleen <input type="checkbox"/> C51 - Malignant neoplasm of vulva <input type="checkbox"/> C52 - Malignant neoplasm of vagina <input type="checkbox"/> C53 - Malignant neoplasm of cervix uteri <input type="checkbox"/> C54 - Malignant neoplasm of corpus uteri <input type="checkbox"/> C58 - Malignant neoplasm of placenta <input type="checkbox"/> C60.0 - Malignant neoplasm of prepuce <input type="checkbox"/> C60.1 - Malignant neoplasm of glans penis <input type="checkbox"/> C63.2 - Malignant neoplasm of scrotum <input type="checkbox"/> C26.9 - Malignant neoplasm of ill-defined sites withi. <input type="checkbox"/> C60.8 - Malignant neoplasm of overlapping sites of penis <input type="checkbox"/> C62.90 - Malignant neoplasm of unspecified testis <input type="checkbox"/> C62.91 - Malignant neoplasm of right testis unspecified <input type="checkbox"/> C62.92 - Malignant neoplasm of left testis unspecified <input type="checkbox"/> C63.7 - Malignant neoplasm of other specified male genital <input type="checkbox"/> C63.8 - Malignant neoplasm of overlapping sites of male genital <input type="checkbox"/> C62.00 - Malignant neoplasm of unspecified undescended testis <input type="checkbox"/> C62.01 - Malignant neoplasm of undescended right testis <input type="checkbox"/> C62.02 - Malignant neoplasm of undescended left testis <input type="checkbox"/> C62.10 - Malignant neoplasm of unspecified descended testis <input type="checkbox"/> C63.10 - Malignant neoplasm of unspecified spermatic cord <input type="checkbox"/> C57 - Malignant unspecified female genital organs | <ul style="list-style-type: none"> <input type="checkbox"/> C18.7 - Malignant neoplasm of sigmoid colon <input type="checkbox"/> C22.7 - Other specified carcinomas of liver <input type="checkbox"/> C60.2 - Malignant neoplasm of body of penis <input type="checkbox"/> C16.3 - Malignant neoplasm of pyloric antrum <input type="checkbox"/> C16.2 - Malignant neoplasm of body of stomach <input type="checkbox"/> C18.2 - Malignant neoplasm of ascending colon <input type="checkbox"/> C18.3 - Malignant neoplasm of hepatic flexure <input type="checkbox"/> C18.5 - Malignant neoplasm of splenic flexure <input type="checkbox"/> C18.4 - Malignant neoplasm of transverse colon <input type="checkbox"/> C18.6 - Malignant neoplasm of fundus of stomach <input type="checkbox"/> C21.0 - Malignant neoplasm of anus unspecified <input type="checkbox"/> C21.2 - Malignant neoplasm of cloacogenic zone <input type="checkbox"/> C24.1 - Malignant neoplasm of ampulla of Vater <input type="checkbox"/> C63.02 - Malignant neoplasm of left epididymis <input type="checkbox"/> C16.1 - Malignant neoplasm of fundus of stomach <input type="checkbox"/> C18.9 - Malignant neoplasm of colon unspecified <input type="checkbox"/> C60.9 - Malignant neoplasm of penis unspecified <input type="checkbox"/> C63.01 - Malignant neoplasm of right epididymis <input type="checkbox"/> C16.9 - Malignant neoplasm of stomach unspecified <input type="checkbox"/> C19 - Malignant neoplasm of rectosigmoid junction <input type="checkbox"/> C63.12 - Malignant neoplasm of left spermatic cord <input type="checkbox"/> C15.9 - Malignant neoplasm of esophagus unspecified <input type="checkbox"/> C63.11 - Malignant neoplasm of right spermatic cord <input type="checkbox"/> C24.0 - Malignant neoplasm of extrahepatic bile duct |
|---|--|--|

Additional ICD10 codes:

INFORMED CONSENT

For the purposes of this consent, “I”, “my”, and “your” will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

1. Positive: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
2. Negative: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
3. Variant of Uncertain Significance (VUS): A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
4. Unexpected Results: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care. Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information **Novalab Corp** used to interpret my results.

Healthcare providers can contact **Novalab Corp** at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient’s sample can help with the interpretation of the test results. These tests are often referred to as “trio tests” since they typically include samples from the patient and both parents. Samples from relatives should be submitted with the patient’s sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that **Novalab Corp** will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.
2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

INTERNATIONAL SAMPLES

If I reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my residence.

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. **Novalab Corp** will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made. I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. **Novalab Corp** will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this de-identified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. **Novalab Corp** shares this type of information with healthcare providers, scientists, and healthcare databases. **Novalab Corp** will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. **Novalab Corp** believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.

INFORMED CONSENT

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

Applicable Only for Full Exome Sequencing and Genome Sequencing Tests. • Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT? - All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES? - The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS - Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified, or reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE - For insurance billing, I understand and authorize **Novalab Corp** to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by **Novalab Corp** as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by **Novalab Corp** on my behalf, I agree to endorse the insurance check and forward it to **Novalab Corp** within 30 days of receipt as payment towards **Novalab Corp** claim for services rendered.

MEDICARE

A completed Advance Beneficiary Notice (ABN) is required for Medicare patients.

DIGITAL PATIENT LETTER CONSENT

• Applicable Only for Commercial Insurance

• Estimate is provided by your health insurance company and therefore NO estimate will be sent for any orders placed with federal or state-funded insurance plans (e.g. Medicare, Medicaid, Tricare, etc.), institutional bill, or patient bill (self-pay).

To provide you with the estimated out-of-pocket expenses related to your test, **Novalab Corp** will send you an email and/or text with the link to access your personalized Digital Patient Letter.

In order to send this information, we need your consent and agreement to the following items:

1. can use your email address or mobile phone number solely for the purpose of **Novalab Corp** sending your estimated financial obligation. Text message data rates may apply. is not responsible for undelivered messages due to incorrect or illegible contact information.
2. will send you an email and/or text message containing a link to view your personalized Patient Letter that includes the test out-of-pocket estimate. The link is time-sensitive and will only be available for 72 hours from the time the message is sent. In order to view the estimate, you must click the link in the message.
3. If you take no action, **Novalab Corp** will assume that you agree to move ahead with testing and will bill your health insurance. You can approve testing with insurance, switch to self-pay, or cancel the test via the link within the given 72-hour window. In turn, **Novalab Corp** if receives your sample(s) and the billing method hasn't been changed, or the test hasn't been cancelled, we will move ahead with testing as ordered, and you will be responsible for any out-of-pocket costs for the completion of the test(s).

STOP Patient Signature

I hereby assign all rights and benefits under my health plan and all rights and obligations that I and my dependents have under my health plan to **Novalab Corp** its assigned affiliates and authorized representatives for laboratory services furnished to me by **Novalab Corp**. I irrevocably designate, authorize and appoint **Novalab Corp** or its assigned affiliates and their authorized representatives as my true and lawful attorney-in-fact for the purpose of submitting my claims, obtain a copy of my health plan document, Summary Plan Description, disclosure, appeal, litigation or other remedies in accordance with the benefits and rights under my health plan and in accordance with federal or state laws. If my health plan fails to abide by my authorization and makes payment directly to me, I agree to endorse the insurance check and forward it to **Novalab Corp** immediately upon receipt. I hereby authorize **Novalab Corp** its assigned affiliates and authorized representatives to contact me or my health Plan/administrator for billing or payment purposes by phone, text message, or email with the contact information that I have provided to **Novalab Corp**, in compliance with federal and state laws. **Novalab Corp**, its assigned affiliates and their authorized representatives may release to my health plan administrator, my employer, and my authorized representative my personal health information for the purpose of procuring payment of **Novalab Corp** and for all the laboratory services. I understand the acceptance of insurance does not relieve me from any responsibility concerning payment for laboratory services and that I am financially responsible for all charges whether or not they are covered by my insurance.

Signature of Patient or Patient Representative / Relationship to Patient

Date:

STOP ORDERING PHYSICIAN SIGN HERE Physician must only order tests that are medically necessary for the diagnosis or treatment of a patient

I attest that this test is medically necessary for the diagnosis or detection of a disease or disorder and that the results will be used in medical management and care decisions for the patient. Furthermore, all information on this Requisition Form is true to the best of my knowledge. I agree to provide the Care Plan notes and Letter of Intent for this order if the insurance requests the lab to gather the medical necessity for any reason

Ordering Physician Signature

Date: